BioNTech SE

📢 JPM 2026|Strategic areas of focus Oncology milestones in 2026: - 7 late-stage data readouts - 6 Phase 3 clinical trial initiations expected - Focus on high-incidence indications, such as lung and breast cancer 📰 bit.ly/3YY5I9L 🎥 bit.ly/3YY5I9L #JPM2026

Tomorrow at #SABCS25, Dr. Schmid will share the study design of the global phase 3 ROSETTA Breast-01 trial evaluating a PD-L1 x VEGF-A bispecific antibody plus chemotherapy in PD-L1 negative TNBC. Join the poster session at 12:30pm CST in Exhibit Hall.

🔬 At #SABCS25, we shared interim global Phase 2 data from our investigational bispecific antibody program in metastatic #TNBC with our partner @bmsnews Learn more in our press release: bit.ly/48CnnrC #BreastCancerResearch #OncologyScience #BioNTech

Tomorrow at #SABCS25, Dr. Schmid will present preliminary data from a global multicohort phase 2 trial of a PD-L1 x VEGF-A bispecific antibody plus chemotherapy for 1L/2L+ locally advanced/metastatic TNBC.

Today, together with OncoC4, we announced data on an investigational selective Treg modulator candidate in patients with advanced sqNSCLC. Learn more in our press release: bit.ly/4oGMM9U #LungCancer #NACLC25

Global interim Phase 2 data in extensive-stage small cell lung cancer presented at #WCLC25: Investigational approach designed to target PD-L1 and VEGF-A in a single molecule. Full PR: bit.ly/3I1dZVs

Visit us at Booth #106.

Small cell lung cancer is a key focus at #BioNTech with multiple trials across disease stages. At #WCLC25, we share global interim Phase 2 data on our PD-L1xVEGF-A bispecific antibody candidate in extensive-stage small cell lung cancer.

We are partnering with @bmsnews to jointly develop and commercialize our PD-L1xVEGF bispecific #antibody candidate BNT327. Combining our expertise, resources, and global reach, we aim to bring novel combination therapies to patients with #cancer. 🚀 investors.biontech.de/news-releases/…

🔗 Highlights of our oncology programs to be presented at ASCO:  bit.ly/4k9r9xi

At #BioNTech, we’re looking forward to #ASCO25, presenting oncology pipeline progress: mRNA cancer immunotherapies, ADCs, and next-gen immunomodulators and targeted therapies. 🗓 May 30 – June 3 | Chicago 📍 Booth #35165 #CancerResearch #ImmunoOncology #OncologyInnovation

🔗 Read more about our Q1 updates (including our forward-looking statements): investors.biontech.de/news-releases/…

Today, we shared our Q1 2025 results and updates on our business & pipeline. We also shared the news on a leadership transition: Jens Holstein will retire as planned and hand over the #newCFO role to Ramón Zapata as of July 1. Thank you, Jens! And welcome, Ramón Zapata. #BioNTech

Explore more about the data: investors.biontech.de/news-releases/…

At #AACR25, we will present data from our #mRNA and immuno-oncology priority programs. These data support execution of our combination strategy in oncology, including first data on the novel combination of our PD-L1xVEGF-A antibody candidate in combination with #ADCs.

We aim to tackle one of the most lethal cancers worldwide: #LungCancer. This week, we are joining the global community at the #ELCC25 presenting new data for our PD-L1/VEGF-A bispecific antibody candidate in metastatic #SCLC. 👉Learn more about the data: investors.biontech.de/encrypted-node…

👉Link to PR and forward-looking statements disclaimer: investors.biontech.de/news-releases/…

🚀 Update: We completed the acquisition of Biotheus. This strengthens our capabilities to develop, manufacture and commercialize next-gen bispecific antibodies, including BNT327 (PD-L1xVEGF-A bispecific), and supports the global execution of our oncology strategy.

📊 Interim Ph1b/2 data for anti-PD-L1/VEGF-A bispecific antibody candidate BNT327 show a 73.8% cORR and a manageable safety profile (primary endpoints) with a mature 18-month OS rate of 69.7% (secondary endpoint) in 1L TNBC at #SABCS24. 👉 Find out more: investors.biontech.de/static-files/9…

We are excited to be attending this year’s #SABCS24, with new interim Phase 1b/2 data for our anti-PD-L1/VEGF-A bispecific antibody candidate BNT327/PM8002 in triple-negative #BreastCancer (#TNBC). 📍Visit us at booth # 226 to explore the latest data for this asset.